Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation
Protein Science · 2026-02 · 35 (2)
DOI: 10.1002/pro.70472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, online erschienen am 28.01.2026. Verfasst von Bhanu Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Structural Bioinformatics Lab, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases, Phosphodiesterase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
In preclinical models, Phosphodiesterase‐10A (PDE10A) inhibition has shown efficacy for Parkinson's and Huntington's diseases and is potentially a therapeutic approach for schizophrenia. In this study, computational approaches were employed to identify selective PDE10A inhibitors from a series of olefinated benzosuberene analogues. The molecular interactions and docking scores of the selected molecules were compared with three different co‐crystal inhibitors of PDE10A. Molecular dynamics (MD) simulations confirmed the stability of the screened hit molecules with PDE10A, and AMKPD‐52 was found to uniquely interact with the selectivity pocket residue Tyr‐683. Further refinement using steered MD simulations and umbrella sampling simulations with a total simulation time of ~72 μs reinforced AMKPD‐52 as the potential lead molecule. Absolute binding free energy calculations performed using multistate Bennett acceptance ratio method consistently ranked AMKPD‐52 as the potential lead molecule for PDE10A inhibition. Experimental evaluation revealed an IC₅₀ value of 11.52 μM for AMKPD‐52, confirming its inhibitory activity against PDE10A. Although the binding affinity and potency were modest compared to the reference inhibitor TAK‐063, the natural origin and straightforward synthetic tractability of AMKPD‐52 make it an attractive candidate for further medicinal chemistry optimization. These findings warrant in vivo validation to assess the therapeutic potential of AMKPD‐52 in PDE10A‐targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Structural Bioinformatics Lab, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India.
- Academy of Scientific and Innovative Research, Ghaziabad, India.
- Chemical Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India.
Förderung
- Council of Scientific and Industrial Research, India
Zitieren
APA
Sharma, B., Singh, R., Kumar, A., Das, P., & Purohit, R. (2026). Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation. Protein Science, 35(2). https://doi.org/10.1002/pro.70472
Vancouver
Sharma B, Singh R, Kumar A, Das P, Purohit R. Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation. Protein Science. 2026;35(2). doi:10.1002/pro.70472
BibTeX
@article{Sharma2026,
author = {Sharma, Bhanu and Singh, Rahul and Kumar, Ashish and Das, Pralay and Purohit, Rituraj},
title = {Expanding the therapeutic landscape of PDE10A inhibition through alchemical absolute binding free energy calculations and in‐vitro evaluation},
journal = {Protein Science},
year = {2026},
volume = {35},
number = {2},
doi = {10.1002/pro.70472}
}
EUVIMED